Cardiac anticoagulation therapy plays a pivotal role in the nuanced landscape of cardiovascular care. Tailored to individuals at risk of blood clot formation, this specialized therapy is a key element in preventing potential complications such as strokes or heart attacks. Commonly prescribed for conditions like atrial fibrillation, deep vein thrombosis, or those with mechanical heart valves, cardiac anticoagulation therapy involves the use of medications like warfarin or direct oral anticoagulants. These medications exert their effect by disrupting the blood clotting process, promoting a smoother flow of blood through the heart and vessels. The meticulous administration of cardiac anticoagulation therapy demands vigilant monitoring and personalized dosing to strike an optimal balance between preventing clots and minimizing the risk of bleeding complications. As research in the medical field progresses, ongoing refinements in cardiac anticoagulation therapies hold the promise of enhanced efficacy, reduced side effects, and improved overall outcomes for individuals managing cardiovascular conditions.
Title : Chronic angina and the health economics of cardiovascular risk reduction in macro- and microvascular coronary disease
Uwe Peter Tigor, Auxilius Pharma, United States
Title : Vericiguat Inhibits the Progress of Cardiac Hypertrophy and Prevents Hypertrophy Induced Heart Failure by Multiple Mechanisms
Guo Wei He, Tianjin University, China
Title : Not So Idiopathic After All: Genotype, Phenotype and IL-1 Blockade Response Converge in Recurrent Pericarditis
burcu yagmur, Kyrenia University Hospital, Cyprus
Title : Beyond the Heart in Cardiovascular Magnetic Resonance Imaging: Prevalence and Clinical Significance of Incidental Extracardiac Findings
burcu yagmur, Kyrenia University Hospital, Cyprus
Title : Cardiovascular mortality in colon cancer a patient characteristics analysis: Population-based study
Nouf, KAU, Saudi Arabia
Title : Improving Screening and Treatment of Iron Deficiency in Patients with Heart Failure with Reduced Ejection Fraction: A Two-Cycle Quality Improvement Project
Danish Malik, University Hospitals Dorset NHS Foundation Trust, United Kingdom